Evidence map›Paper›PMID 38984568›Full record

ReviewRecent patents on nanotechnology2025

A Patent Analysis on Nano Drug Delivery Systems.

Dengyu Li, Wen Luo, Shengwei Yin, Ying Wang, Yanqing Zhao, Shiwei Zhu, Junfeng Yu, Ping Yang, Lina Zhang, Zhuyan Xi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent patents on nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dengyu LiInformation Research Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.ORCID 0000-0001-6320-4535
Wen LuoInformation Research Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.
Shengwei YinSchool of Medicine, Eastern Liaoning University, Dandong, China.
Ying WangScience and Technology Service Platform, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.
Yanqing ZhaoInformation Research Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.
Shiwei ZhuInformation Research Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.
Junfeng YuInformation Research Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.
Ping YangInformation Research Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.
Lina ZhangInformation Research Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.
Zhuyan XiScience and Technology Service Platform, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China.

Funding

Shandong Key R&D Program 2023RZB04032, 2023RZB04036, 2023RKY02009
6 · The paper itself

Abstract

backgroundA nano drug delivery system is an effective tool for drug delivery and controlled release, which is used for a variety of medical applications. In recent decades, nano drug delivery systems have been significantly developed with the emergence of new nanomaterials and nanotechnologies.

objectiveThis article aimed to provide insight into the technological development of nano drug delivery systems through patent analysis.

methods3708 patent documents were used for patent analysis after retrieval from the Incopat patent database.

resultsThe number of patents on nano drug delivery systems has shown a rapid growth trend in the past two decades. At present, China and the United States have obvious contributions to the number of patents. According to the patent data, the nanomaterials used in nano drug delivery system are mainly inorganic nanomaterials, lipid-based nanomaterials, and macromolecules. In recent years, the highly cited patents (≥14) for nano drug delivery systems mainly involve lipid-based nanomaterials, indicating that their technology is mature and widely used. The inorganic nanomaterials in drug delivery have received increasing attention, and the number of related patents has increased significantly after 2016. The number of highly cited patents in the United States is 250, which is much higher than in other countries.

conclusionEven after decades of development, nano drug delivery systems remain a hot topic for researchers. The significant increase in patents since 2016 can be attributed to the large number of new patents from China. However, according to the proportion of highly cited patents in total, China's patented technologies in nano drug delivery systems are not advanced enough compared to developed countries, including the United States, Canada, Germany, and France. In the future, research on emerging nanomaterials for nano drug delivery systems, such as inorganic nanomaterials, may focus on developing new materials and optimising their properties. The lipid-based and polymer- based nanomaterials can be continuously improved for the development of new nanomedicines.

Indexed as

Drug Delivery SystemsNanoparticle Drug Delivery SystemNanostructuresNanotechnologyPatents as TopicChinaHumansLipidsNanoparticlesUnited StatesLipidsNanoparticle Drug Delivery SystemDrug deliveryinorganic nanomaterialslipidmacromoleculenanocarriernanomaterialspatent analysis.

Identifiers

PMID38984568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.